JP2010539192A - ノロウイルスに対して防御免疫応答を付与する方法 - Google Patents

ノロウイルスに対して防御免疫応答を付与する方法 Download PDF

Info

Publication number
JP2010539192A
JP2010539192A JP2010525114A JP2010525114A JP2010539192A JP 2010539192 A JP2010539192 A JP 2010539192A JP 2010525114 A JP2010525114 A JP 2010525114A JP 2010525114 A JP2010525114 A JP 2010525114A JP 2010539192 A JP2010539192 A JP 2010539192A
Authority
JP
Japan
Prior art keywords
norovirus
vaccine
vlp
virus
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010525114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539192A5 (https=
Inventor
リチャードソン，チャールズ
ヴェドヴィック，トーマス，エス．
フォーベルト，トーマス，アール．
Original Assignee
リゴサイト ファーマスーティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010539192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by リゴサイト ファーマスーティカルズ，インコーポレイテッド filed Critical リゴサイト ファーマスーティカルズ，インコーポレイテッド
Publication of JP2010539192A publication Critical patent/JP2010539192A/ja
Publication of JP2010539192A5 publication Critical patent/JP2010539192A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2010525114A 2007-09-18 2008-09-18 ノロウイルスに対して防御免疫応答を付与する方法 Pending JP2010539192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97338907P 2007-09-18 2007-09-18
US98682607P 2007-11-09 2007-11-09
PCT/US2008/076763 WO2009039229A2 (en) 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014095094A Division JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法

Publications (2)

Publication Number Publication Date
JP2010539192A true JP2010539192A (ja) 2010-12-16
JP2010539192A5 JP2010539192A5 (https=) 2011-11-04

Family

ID=40468754

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010525114A Pending JP2010539192A (ja) 2007-09-18 2008-09-18 ノロウイルスに対して防御免疫応答を付与する方法
JP2014095094A Active JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法
JP2016149168A Active JP6615063B2 (ja) 2007-09-18 2016-07-29 ノロウイルスに対して防御免疫応答を付与する方法
JP2019107207A Withdrawn JP2019163328A (ja) 2007-09-18 2019-06-07 ノロウイルスに対して防御免疫応答を付与する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014095094A Active JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法
JP2016149168A Active JP6615063B2 (ja) 2007-09-18 2016-07-29 ノロウイルスに対して防御免疫応答を付与する方法
JP2019107207A Withdrawn JP2019163328A (ja) 2007-09-18 2019-06-07 ノロウイルスに対して防御免疫応答を付与する方法

Country Status (9)

Country Link
US (5) US10130696B2 (https=)
EP (1) EP2190471A4 (https=)
JP (4) JP2010539192A (https=)
KR (2) KR20150129042A (https=)
CN (2) CN104740624B (https=)
AU (1) AU2008302276B2 (https=)
CA (1) CA2698397C (https=)
SG (2) SG10201601660YA (https=)
WO (1) WO2009039229A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510073A (ja) * 2011-03-11 2014-04-24 マクマスター・ユニヴァーシティ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
JP2014520852A (ja) * 2011-07-11 2014-08-25 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
WO2015004995A1 (ja) * 2013-07-12 2015-01-15 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
JP2017178890A (ja) * 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
JP2018526437A (ja) * 2015-08-28 2018-09-13 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
JP2022514759A (ja) * 2018-12-20 2022-02-15 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤及び方法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066354B1 (en) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
WO2008113011A2 (en) 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
NO2324113T3 (https=) 2008-08-08 2018-07-28
US20120121710A1 (en) 2009-03-27 2012-05-17 Arizona Board Of Regents For And On Behalf Of Arizona State University Mucosal Immunization
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
AU2011276328C1 (en) * 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CA2851917A1 (en) * 2011-10-12 2013-04-18 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
CN102559616B (zh) * 2012-02-24 2014-01-01 河南科技大学 一种含诺如病毒rna片段的假病毒颗粒及其制备方法
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN106103720A (zh) 2013-10-03 2016-11-09 武田疫苗股份有限公司 自细胞系检测和除去弹状病毒的方法
EP3116479A1 (en) * 2014-03-12 2017-01-18 GlaxoSmithKline Biologicals S.A. Liposomal compositions for mucosal delivery
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
US20210308249A1 (en) * 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115677838A (zh) * 2021-07-29 2023-02-03 成都康华生物制品股份有限公司 六价诺如病毒VLPs疫苗及其制备方法
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
EP0635056A1 (en) 1992-04-08 1995-01-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Wild-type measles virus glycoproteins: vaccine and detection method therefor
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
PT973546E (pt) 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
HUP0103091A3 (en) 1998-08-14 2002-03-28 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
WO2000035479A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
AU764138B2 (en) 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
KR100771402B1 (ko) 1999-06-22 2007-10-30 국립감염증연구소장이 대표하는 일본국 Ｓｒｓｖ 검출 킷트
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20040121465A1 (en) 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
CA2514667C (en) 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
US20040213745A1 (en) 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US20060177468A1 (en) 2005-01-05 2006-08-10 Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine Delivery vehicles, bioactive substances and viral vaccines
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
ZA200707413B (en) 2005-03-18 2009-01-28 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
BRPI0611336A2 (pt) 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
EP2066354B1 (en) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
WO2008113011A2 (en) 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
NO2324113T3 (https=) 2008-08-08 2018-07-28
WO2010084298A1 (en) 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CA2787666A1 (en) 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP4112074A1 (en) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
EP3827838B1 (en) 2015-12-16 2023-06-07 The Walter and Eliza Hall Institute of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
KR20210005240A (ko) 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
US20210308249A1 (en) 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
PE20211959A1 (es) 2019-02-15 2021-09-30 Editas Medicine Inc Celulas asesinas naturales (nk) modificadas para inmunoterapia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013004327; ＬｉｇｏＣｙｔｅ　Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，　Ｉｎｃ．: 'ＬＩＧＯＣＹＴＥ　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬＳ　ＩＮＩＴＩＡＴＥＳ　Ｕ．Ｓ．　ＣＬＩＮＩＣＡＬ　ＴＲＩＡＬ　ＯＦ　ＮＯＲＯＶＩＲＵＳ　ＶＡＣＣＩＮＥ' ［ｏｎｌｉｎｅ］ , 20070403 *
JPN6013004328; Ｖａｃｃｉｎｅ Ｖｏｌ．２１，　Ｎｏ．５-６, 2003, ｐ．３７６-３８５ *
JPN6013004329; Ｖａｃｃｉｎｅ Ｖｏｌ．２２，　Ｎｏ．９-１０, 2004, ｐ．１０７９-１０８６ *
JPN6013004330; Ｂｉｏｍｏｌｅｃｕｌａｒ　Ｅｎｇｉｎｅｅｒｉｎｇ Ｖｏｌ．１８，　Ｎｏ．３, 2001, ｐ．６９-８５ *
JPN6013004332; Ｖａｃｃｉｎｅ Ｖｏｌ．２４，　Ｎｏ．２４, 2006, ｐ．５２２０-５２３４ *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821054B2 (en) 2011-03-11 2017-11-21 Turnstone Limited Partnership Method of vaccination comprising a histone deacetylase inhibitor
JP2014510073A (ja) * 2011-03-11 2014-04-24 マクマスター・ユニヴァーシティ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
JP2014520852A (ja) * 2011-07-11 2014-08-25 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
JP2017214357A (ja) * 2011-07-11 2017-12-07 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
WO2015004995A1 (ja) * 2013-07-12 2015-01-15 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
JP2018526437A (ja) * 2015-08-28 2018-09-13 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
JP7033534B2 (ja) 2015-08-28 2022-03-10 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
US11596680B2 (en) 2015-08-28 2023-03-07 Resilience Government Services, Inc. Norovirus vaccine
JP2017178890A (ja) * 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
US11633467B2 (en) 2018-02-15 2023-04-25 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
JP2022514759A (ja) * 2018-12-20 2022-02-15 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤及び方法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
KR20240145520A (ko) 2022-03-18 2024-10-07 덴카 주식회사 링커에 의해 연결된 캡시드 단백질을 포함하는 바이러스 유사입자

Also Published As

Publication number Publication date
CN104740624B (zh) 2018-04-24
JP2019163328A (ja) 2019-09-26
US10130696B2 (en) 2018-11-20
US20190381164A1 (en) 2019-12-19
US20200345827A1 (en) 2020-11-05
EP2190471A4 (en) 2012-05-09
HK1211473A1 (en) 2016-05-27
US10688174B2 (en) 2020-06-23
CN101918028B (zh) 2015-01-07
CN104740624A (zh) 2015-07-01
US11826415B2 (en) 2023-11-28
CA2698397A1 (en) 2009-03-26
JP6615063B2 (ja) 2019-12-04
KR20100083150A (ko) 2010-07-21
US20110182975A1 (en) 2011-07-28
JP2014141528A (ja) 2014-08-07
AU2008302276B2 (en) 2013-10-10
US11040097B2 (en) 2021-06-22
JP2016196502A (ja) 2016-11-24
AU2008302276A1 (en) 2009-03-26
CA2698397C (en) 2018-03-27
JP6296885B2 (ja) 2018-03-20
US20240316175A1 (en) 2024-09-26
SG10201601660YA (en) 2016-04-28
WO2009039229A2 (en) 2009-03-26
CN101918028A (zh) 2010-12-15
WO2009039229A3 (en) 2009-09-03
US20220143169A1 (en) 2022-05-12
SG184733A1 (en) 2012-10-30
KR20150129042A (ko) 2015-11-18
EP2190471A2 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
US11826415B2 (en) Method of conferring a protective immune response to Norovirus
JP6613259B2 (ja) 非経口ノロウイルスワクチン製剤
US9821049B2 (en) Method of conferring a protective immune response to Norovirus
US9861691B2 (en) Norovirus vaccine formulations
AU2014200084B2 (en) Method of conferring a protective immune response to norovirus
AU2016250345A1 (en) Method of conferring a protective immune response to norovirus
HK1211473B (en) Vaccine of conferring a protective immune response to norovirus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140502

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140707

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140815